Journal of Shandong University (Health Sciences) ›› 2026, Vol. 64 ›› Issue (3): 124-130.doi: 10.6040/j.issn.1671-7554.0.2025.0700

• Frontier Progress • Previous Articles    

A new drug for non-small cell lung cancer: Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met protein

HUANG Peiwen, WANG Xudong   

  1. Department of Pharmacy, The Third Affiliated Hospital of Anhui Medical University/Hefei First Peoples Hospital, Hefei 230061, Anhui, China
  • Published:2026-03-19

PDF (PC)

2

Abstract: Telisotuzumab Vedotin is an antibody-drug conjugate targeting c-Met protein. Telisotuzumab Vedotin was approved for adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer with high c-Met protein expression by the U.S. Food and Drug Administration on May 14, 2025. Telisotuzumab Vedotin is the first c-Met-targeted antibody-drug conjugate approved for clinical use.The mechanism,pharmacokinetics,clinical research and safety of Telisotuzumab Vedotin were reviewed in this article.

Key words: Telisotuzumab Vedotin, Antibody-drug conjugate, c-Met protein, Non-small cell lung cancer, Action mechanism, Clinical research

CLC Number: 

  • R979.1
[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263.
[2] American Cancer Society.Cancer facts & figures 2025[EB/OL].(2025-05-16)[2025-06-22]. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2025/2025-cancer-facts-and-figures-acs.pdf
[3] 艾静, 杜玉萍, 王崇霖, 等. 197例早期非小细胞肺癌患者营养风险状况及其相关因素[J]. 卫生研究, 2025, 54(3): 444-448. AI Jing, DU Yuping, WANG Chonglin, et al. Nutritional risk investigation and related factors of 197 patients with early-stage non-small cell lung cancer[J].Journal of Hygiene Research, 2025, 54(3): 444-448.
[4] Tsakonas G, Botling J, Micke P, et al. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer[J]. Lung Cancer, 2019, 133: 69-74. doi: 10.1016/j.lungcan.2019.04.028
[5] Awad MM, Oxnard GR, Jackman DM, et al. MET exon 14 mutations in non-small-cell lung cancer are associated with advanced age and stage-dependent MET genomic amplification and c-Met overexpression[J]. J Clin Oncol, 2016, 34(7): 721-730.
[6] 高洋, 项鹏程, 岳林, 等. 非小细胞肺癌中PD-L1与C-Met基因表达的相关性研究[J]. 诊断病理学杂志, 2021, 28(12): 1066-1071.
[7] 赵博晨, 路丹. c-Met 在肺癌中的研究进展[J]. 现代肿瘤医学, 2022, 30(1): 174-178. ZHAO Bochen, LU Dan. Research progress of c-Met in lung cancer[J]. Modern Oncology, 2022, 30(1): 174-178.
[8] Zhan ST, Li JF, Cheng B, et al. Landscape of c-Met overexpression in non-small cell lung cancer: a large-scale study of clinicomolecular features and prognosis based on Chinese data[J]. Ther Adv Med Oncol,2024,16:17588359241279715. doi: 10.1177/17588359241279715
[9] Bai QM, Shi XH, Zhou XY, et al. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer[J]. Ther Adv Med Oncol, 2024, 16: 17588359231216096. doi: 10.1177/17588359231216096
[10] FDA. FDA grants accelerated approval to Emrelis[EB/OL].(2025-05-14)[2025-06-22]. https://www.drugs.com/newdrugs/fda-grants-accelerated-approval-emrelis-telisotuzumab-vedotin-tllv-non-small-cell-lung-cancer-c-met-6519.html
[11] Strickler JH, Weekes CD, Nemunaitis J, et al. First-in-human phase I, dose-escalation and -expansion study of Telisotuzumab Vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors[J]. J Clin Oncol, 2018, 36(33): 3298-3306.
[12] Wang JY, Anderson MG, Oleksijew A, et al. ABBV-399, a c-Met antibody drug conjugate that targets both MET amplified and c-Met overexpressing tumors, irrespective of MET pathway dependence[J]. Clin Cancer Res, 2017, 23(4): 992-1000.
[13] Mer AH, Mirzaei Y, Misamogooe F, et al. Progress of antibody-drug conjugates(ADCs)targeting c-Met in cancer therapy; insights from clinical and preclinical studies[J]. Drug Deliv Transl Res, 2024, 14(11): 2963-2988.
[14] 李雨凝, 苏佳琳, 罗永忠, 等. 抗体药物偶联物治疗非小细胞肺癌的研究进展和展望[J]. 肿瘤药学, 2024, 14(4): 411-419. LI Yuning, SU Jialin, LUO Yongzhong, et al. Research progress and prospect of antibody-drug conjugates in the treatment of non-small cell lung cancer[J]. Anti-Tumor Pharmacy, 2024, 14(4): 411-419.
[15] 沈娟, 刘炬, 于蒙蒙, 等. 抗体偶联药物组成及质量控制概述[J]. 解放军药学学报, 2025, 38(2): 209-215. SHEN Juan, LIU Ju, YU Mengmeng, et al. A surveyof composition and quality control of antibody-drug conjugates[J]. Pharmaceutical Journal of Chinese Peoples Liberation Army, 2025, 38(2): 209-215.
[16] Kwak Y, Kim SI, Park CK, et al. C-MET overexpression and ampliffcation in gliomas[J]. Int J Clin Exp Pathol, 2015, 8(11): 14932-14938.
[17] Remon J, Hendriks LEL, Mountzios G, et al. MET alterations in NSCLC-current perspectives and future challenges[J]. J Thorac Oncol, 2023, 18(4): 419-435.
[18] Wang JY, Goetsch L, Tucker L, et al. Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification[J]. BMC Cancer, 2016, 16: 105. doi: 10.1186/s12885-016-2138-z
[19] Gonzalez A, Broussas M, Beau-Larvor C, et al. A novel antagonist anti-cMet antibody with antitumor activities targeting both ligand-dependent and ligand-independent c-Met receptors[J]. Int J Cancer, 2016, 139(8): 1851-1863.
[20] 罗梦珺, 张丽瑾, 陈涛. c-Met在非小细胞肺癌中的作用及中药干预的研究进展[J]. 生命的化学, 2021, 41(1): 84-90. LUO Mengjun, ZHANG Lijin, CHEN Tao. Role of c-Met in non-small cell lung cancer and research progress in the intervention of traditional Chinese medicine[J]. Chemistry of Life, 2021, 41(1): 84-90.
[21] Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced non-squamous EGFR-wildtype NSCLC in the Phase 2 LUMINOSITY trial[J]. J Clin Oncol, 2024, 42(25): 3000-3011.
[22] Horinouchi H, Cho BC, Camidge DR, et al. Results from a phase 1b study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small cell lung cancer(NSCLC)after progression on prior osimertinib[J]. Ann Oncol, 2025, 36(5): 583-591.
[23] FDA. EMRELISTM(telisotuzumab vedotin-tllv)for injection, for intravenous use[EB/OL].(2025-05-14)[2025-06-22]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761384s000lbl.pdf
[24] Camidge DR, Barlesi F, Goldman JW, et al. A phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC[J]. JTO Clin Res Rep, 2021, 3(1): 100262. doi: 10.1016/j.jtocrr.2021.100262
[25] Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib study of Telisotuzumab Vedotin in combination with erlotinib in patients with c-Met protein-expressing non small-cell lung cancer[J]. J Clin Oncol, 2023, 41(5): 1105-1115.
[26] NIH. A Study evaluating the safety, pharmacokinetics(PK), and preliminary efficacy of ABBV-399 in participants with advanced solid tumors[EB/OL].(2025-02 -26)[2025-06-22]. https://clinicaltrials.gov/study/NCT02099058?term=Telisotuzumab%20Vedotin&rank=6
[27] NIH. A study to assess disease activity and adverse events of intravenous(IV)Telisotuzumab Vedotin compared to IV docetaxel in adult participants with previously treated non-squamous non-small cell lung cancer(NSCLC)[EB/OL].(2025-05-29)[2025-06-22. https://clinicaltrials.gov/study/NCT04928846?term=Telisotuzumab%20Vedotin&rank=5
[28] NIH. A study to assess adverse events and how intravenously(IV)infused Telisotuzumab Vedotin(ABBV-399)moves through the body as a monotherapy in adult participants with previously treated non-squamous non-small cell lung cancer(NSCLC)[EB/OL].(2025-05-29)[2025-06-22]. https://clinicaltrials.gov/study/NCT06568939?term=Telisotuzumab%20Vedotin&rank=2&tab=table
[29] Müller P, Martin K, Theurich S, et al. Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells[J]. Cancer Immunol Res, 2014, 2(8): 741-755.
[1] ZHAO Hanqing, ZHOU Xinrui, LI Zijian, TANG Xing. Application of circulating tumor cells combined with serological detection in non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(5): 79-85.
[2] XU Nianxing, WEI Dong, QIAO Junjie, ZHAN Bingyan. Predictive value of CD8+, IL-6, and PaO2 for immunotherapy-triggered radiation recall pneumonitis in unresectable stage ⅢB/C and IV non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(2): 29-35.
[3] Thoracoscopic Committee of Shandong Provincial Endoscopic Surgery Quality Control Center. Shandong Provincial expert consensus on control indexes of VATS/RATS perioperative quality for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2025, 63(12): 1-5.
[4] LIU Zhenkun, LYU Jiling, XU Weiwei, MA Litian, ZHANG Caiqing. Value of tNGS testing and conventional culture for BALF in the diagnosis of NSCLC complicated with IPFD [J]. Journal of Shandong University (Health Sciences), 2025, 63(11): 36-45.
[5] WANG Fengyan, LIANG Zhenyu, LI Xueping, CHEN Rongchang. Clinical research hotspots of chronic obstructive pulmonary disease in recent years [J]. Journal of Shandong University (Health Sciences), 2024, 62(5): 7-15.
[6] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[7] CHEN Zhaobo, FANG Min, XUE Haoran, LIU Chunyan. Deubiquitinase USP35 promotes the cells migration and invasion of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 30-37.
[8] MA Ruijie, ZHU Liangming, ZUO Taiyang, LI Chunhai, ZHANG Nan, SUN Zhigang. Prognosis of microwave ablation for pulmonary oligometastases after radical resection of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(12): 63-68.
[9] Huining LIU,Jun PENG,Yingchun REN,Guang YANG,Wenhao WANG,Jinfeng LIU,Qing TIAN. Comparison of 34 cases of thoracoscopic wedge resection and 21 cases of segmental resection for stage ⅠA1 non-small cell lung cancer in area P [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 38-43.
[10] DING Zichen, WANG Haohua, ZHOU Liwen, CONG Huiwen, LI Chengsheng, BAO Qihan, YANG Yi, WANG Lianyuan, WANG Suzhen, SHI Fuyan. Study on the individualized efficacy for non-small cell lung cancer patients based on Bayesian Additive Regression Tree model [J]. Journal of Shandong University (Health Sciences), 2022, 60(10): 92-98.
[11] LIU Xiaojing, XIA Xiyan, XIAO Ke, CHEN Wendan, ZHUANG Xuewei. Expression and clinical significance of exosomal long non-coding RNA OGFRP1 in 84 cases of non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2020, 58(11): 71-75.
[12] WEI Ping, DU Lutao, WANG Qing, ZHAN Yao, XIE Yujiao, ZHANG Shujun, DUAN Weili, WANG Chuanxin. Diagnostic value of serum exosomal miR-20b-5p for non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(4): 91-96.
[13] WANG Wei, LIU Yongzheng, LI Ling. Effects of Physalin B on proliferation, migration and apoptosis of human non-small cell lung cancer cells [J]. Journal of Shandong University (Health Sciences), 2019, 57(3): 13-18.
[14] WANG Jianli, WANG Xiaojing, SUN Yulian, HU Xiaole, LUAN Xiaorong. Clinical effect of gefitinib combined with chemotherapy on patients with advanced non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(11): 20-26.
[15] ZHENG Qingyue, ZHAO Qiuhong, QU Xiangyun, DONG Zhaonan, MA Xueqing, JIA Yunli. Diagnosis value of serum exosome miR-205-5p/miR-152-5p on early non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2019, 57(10): 101-106.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd